

## 7 REFERENCES

- Abounader R, Lal B, Luddy C, et al. (2002) In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. *Faseb J*, **16**, 108-10.
- Abu-Duhier FM, Goodeve AC, Wilson GA, et al. (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. *Br J Haematol*, **111**, 190-5.
- Agus DB, Akita RW, Fox WD, et al. (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. *Cancer Cell*, **2**, 127-37.
- Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y, Koza T (2007) Characterization of a novel oncogenic K-ras mutation in colon cancer. *Biochem Biophys Res Commun*, **352**, 728-32.
- Alberici P, Jagmohan-Changur S, De Pater E, et al. (2006) Smad4 haploinsufficiency in mouse models for intestinal cancer. *Oncogene*, **25**, 1841-51.
- Alessi DR, Sakamoto K, Bayascas JR (2006) LKB1-dependent signaling pathways. *Annu Rev Biochem*, **75**, 137-63.
- Alter BP, Rosenberg PS, Brody LC (2007) Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. *J Med Genet*, **44**, 1-9.
- Ando Y, Saka H, Ando M, et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. *Cancer Res*, **60**, 6921-6.
- Aoki Y, Niihori T, Kawame H, et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. *Nat Genet*, **37**, 1038-40.
- Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. *Br J Cancer*, **8**, 1-12.
- Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R (2002) Trastuzumab in the treatment of non-small cell lung cancer. *Semin Oncol*, **29**, 59-65.
- Baas AF, Boudeau J, Sapkota GP, et al. (2003) Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. *Embo J*, **22**, 3062-72.
- Baker SJ, Fearon ER, Nigro JM, et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science*, **244**, 217-21.
- Barancik M, Polekova L, Mrazova T, Breier A, Stankovicova T, Slezak J (1994) Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. *Drugs Exp Clin Res*, **20**, 13-8.
- Bargmann CI, Hung MC, Weinberg RA (1986a) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. *Cell*, **45**, 649-57.
- Bargmann CI, Hung MC, Weinberg RA (1986b) The neu oncogene encodes an epidermal growth factor receptor-related protein. *Nature*, **319**, 226-30.
- Barker PE, Besmer P., Ruddle, F.H. (1985) Human c-kit oncogene on human chromosome 4. *Am J Med Genet*, **37**, abstract.

- Barthe C, Gharbi MJ, Lagarde V, et al. (2002) Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. *Br J Haematol*, **119**, 109-11.
- Baselga J, Tripathy D, Mendelsohn J, et al. (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. *Semin Oncol*, **26**, 78-83.
- Bauer S, Yu LK, Demetri GD, Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. *Cancer Res*, **66**, 9153-61.
- Baxter EJ, Hochhaus A, Bolufer P, et al. (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. *Hum Mol Genet*, **11**, 1391-7.
- Baylin SB (2005) DNA methylation and gene silencing in cancer. *Nat Clin Pract Oncol*, **2 Suppl 1**, S4-11.
- Bell DW, Gore I, Okimoto RA, et al. (2005a) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. *Nat Genet*, **37**, 1315-6.
- Bell DW, Lynch TJ, Haserlat SM, et al. (2005b) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. *J Clin Oncol*, **23**, 8081-92.
- Bell DW, Varley JM, Szydlo TE, et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science*, **286**, 2528-31.
- Berenblum I, Shubik P (1949) The persistence of latent tumour cells induced in the mouse's skin by a single application of 9:10-dimethyl-1:2-benzanthracene. *Br J Cancer*, **3**, 384-6.
- Berger MS, Locher GW, Saurer S, et al. (1988) Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. *Cancer Res*, **48**, 1238-43.
- Beroud C, Soussi T (1996) APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res*, **24**, 121-4.
- Bielschowsky M, Schofield GC (1962) Studies on megacolon in piebald mice. *Aust J Exp Biol Med Sci*, **40**, 395-403.
- Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. *Nat Rev Mol Cell Biol*, **4**, 915-25.
- Birg F, Courcoul M, Rosnet O, et al. (1992) Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. *Blood*, **80**, 2584-93.
- Bonneau D, Longy M (2000) Mutations of the human PTEN gene. *Hum Mutat*, **16**, 109-22.
- Borisy AA, Elliott PJ, Hurst NW, et al. (2003) Systematic discovery of multicomponent therapeutics. *Proc Natl Acad Sci U S A*, **100**, 7977-82.
- Bottaro DP, Rubin JS, Faletto DL, et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*, **251**, 802-4.
- Boveri T (1929) *The origin of malignant tumors.*, Williams and Wilkins Publishing Co.
- Boyse EA, Old LJ, Campbell HA, Mashburn LT (1967) Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among

- leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase. *J Exp Med*, **125**, 17-31.
- Brabender J, Danenberg KD, Metzger R, et al. (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. *Clin Cancer Res*, **7**, 1850-5.
- Branford S, Rudzki Z, Walsh S, et al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. *Blood*, **99**, 3472-5.
- Broome JD (1963) Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. *J Exp Med*, **118**, 121-48.
- Burgess AW, Cho HS, Eigenbrot C, et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. *Mol Cell*, **12**, 541-52.
- Bussey KJ, Chin K, Lababidi S, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. *Mol Cancer Ther*, **5**, 853-67.
- Cantley LC, Auger KR, Carpenter C, et al. (1991) Oncogenes and signal transduction. *Cell*, **64**, 281-302.
- Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. *Nat Rev Drug Discov*, **1**, 493-502.
- Cappuzzo F, Bemis L, Varella-Garcia M (2006) HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. *N Engl J Med*, **354**, 2619-21.
- Cappuzzo F, Magrini E, Ceresoli GL, et al. (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst*, **96**, 1133-41.
- Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. (2005) Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol*, **23**, 5007-18.
- Carballo M, Roig I, Aguilar F, et al. (2005) Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. *Am J Med Genet A*, **132**, 361-4.
- Carboni L, Tacconi S, Carletti R, Bettini E, Ferraguti F (1997) Localization of the messenger RNA for the c-Jun NH2-terminal kinase kinase in the adult and developing rat brain: an in situ hybridization study. *Neuroscience*, **80**, 147-60.
- Carow CE, Levenstein M, Kaufmann SH, et al. (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. *Blood*, **87**, 1089-96.
- Chan CT, Metz MZ, Kane SE (2005) Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. *Breast Cancer Res Treat*, **91**, 187-201.

- Chen PL, Scully P, Shew JY, Wang JY, Lee WH (1989) Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. *Cell*, **58**, 1193-8.
- Cheng HL, Trink B, Tzai TS, et al. (2002) Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. *J Clin Oncol*, **20**, 1544-50.
- Child SJ, Miller MK, Geballe AP (1999) Translational control by an upstream open reading frame in the HER-2/neu transcript. *J Biol Chem*, **274**, 24335-41.
- Cho HS, Mason K, Ramyar KX, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature*, **421**, 756-60.
- Chung DC (2000) The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. *Gastroenterology*, **119**, 854-65.
- Ciampi R, Nikiforov YE (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. *Endocrinology*, **148**, 936-41.
- Clamon G, Herndon J, Kern J, et al. (2005) Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. *Cancer*, **103**, 1670-5.
- Cockman ME, Masson N, Mole DR, et al. (2000) Hypoxia inducible factor- $\alpha$  binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. *J Biol Chem*, **275**, 25733-41.
- Cohen M, Dembling B, Schorling J (2002) The association between schizophrenia and cancer: a population-based mortality study. *Schizophr Res*, **57**, 139-46.
- Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. *Oncologist*, **10**, 461-6.
- Cohen MH, Williams GA, Sridhara R, et al. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. *Clin Cancer Res*, **10**, 1212-8.
- Cools J, DeAngelo DJ, Gotlib J, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med*, **348**, 1201-14.
- Cooper CS, Park M, Blair DG, et al. (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. *Nature*, **311**, 29-33.
- Corbin AS, Buchdunger E, Pascal F, Druker BJ (2002) Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. *J Biol Chem*, **277**, 32214-9.
- Corless CL, McGreevey L, Haley A, Town A, Heinrich MC (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. *Am J Pathol*, **160**, 1567-72.
- Corless CL, Schroeder A, Griffith D, et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol*, **23**, 5357-64.
- Cortes J, Rousselot P, Kim DW, et al. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-

- resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood*, **109**, 3207-13.
- COSMIC Catalogue of Somatic Mutations in Cancer ([www.sanger.ac.uk/genetics/CGP/cosmic](http://www.sanger.ac.uk/genetics/CGP/cosmic)).
- Cowan JM, Halaban R, Francke U (1988) Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. *J Natl Cancer Inst*, **80**, 1159-64.
- Cowley GP, Smith JA, Gusterson BA (1986) Increased EGF receptors on human squamous carcinoma cell lines. *Br J Cancer*, **53**, 223-9.
- Cuenda A, Dorow DS (1998) Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1. *Biochem J*, **333 ( Pt 1)**, 11-5.
- Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nat Rev Cancer*, **6**, 184-92.
- Cunningham SC, Kamangar F, Kim MP, et al. (2006) MKK4 status predicts survival after resection of gastric adenocarcinoma. *Arch Surg*, **141**, 1095-9; discussion 1100.
- da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. *Cancer Res*, **65**, 10686-91.
- Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. *J Clin Oncol*, **23**, 1473-82.
- Dalton SO, Johansen C, Poulsen AH, et al. (2006) Cancer risk among users of neuroleptic medication: a population-based cohort study. *Br J Cancer*, **95**, 934-9.
- Dalton SO, Mellekjaer L, Thomassen L, Mortensen PB, Johansen C (2005) Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. *Schizophr Res*, **75**, 315-24.
- Das J, Chen P, Norris D, et al. (2006) 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. *J Med Chem*, **49**, 6819-32.
- Davies H, Bignell GR, Cox C, et al. (2002) Mutations of the BRAF gene in human cancer. *Nature*, **417**, 949-54.
- Davies RL, Grosse VA, Kucherlapati R, Bothwell M (1980) Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. *Proc Natl Acad Sci U S A*, **77**, 4188-92.
- Dean M, Park M, Le Beau MM, et al. (1985) The human met oncogene is related to the tyrosine kinase oncogenes. *Nature*, **318**, 385-8.
- Debiec-Rychter M, Wasag B, Stul M, et al. (2004) Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. *J Pathol*, **202**, 430-8.

- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg*, **231**, 51-8.
- Demetri GD (2002) Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). *Eur J Cancer*, **38 Suppl 5**, S52-9.
- Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet*, **368**, 1329-38.
- D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G, Jr., Summerhayes IC (1989) Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. *Oncogene*, **4**, 1233-9.
- Demunter A, Ahmadian MR, Libbrecht L, et al. (2001) A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. *Cancer Res*, **61**, 4916-22.
- Der CJ, Krontiris TG, Cooper GM (1982) Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. *Proc Natl Acad Sci U S A*, **79**, 3637-40.
- Derijard B, Raingeaud J, Barrett T, et al. (1995) Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. *Science*, **267**, 682-5.
- Dhomen N, Marais R (2007) New insight into BRAF mutations in cancer. *Curr Opin Genet Dev*, **17**, 31-9.
- Dong B, Valencia CA, Liu R (2007) Ca<sup>2+</sup>/calmodulin directly interacts with the PH domain of AKT1. *J Biol Chem*.
- Donis-Keller H, Dou S, Chi D, et al. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. *Hum Mol Genet*, **2**, 851-6.
- Dowell SP, Hall PA (1994) The clinical relevance of the p53 tumour suppressor gene. *Cytopathology*, **5**, 133-45.
- Downward J (2003) Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer*, **3**, 11-22.
- Downward J, Yarden Y, Mayes E, et al. (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. *Nature*, **307**, 521-7.
- Eberhard DA, Johnson BE, Amler LC, et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol*, **23**, 5900-9.
- Edery P, Lyonnet S, Mulligan LM, et al. (1994) Mutations of the RET proto-oncogene in Hirschsprung's disease. *Nature*, **367**, 378-80.
- Edkins S, O'Meara S, Parker A, et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. *Cancer Biol Ther*, **5**, 928-32.
- Eisen T, Ahmad T, Flaherty KT, et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. *Br J Cancer*, **95**, 581-6.
- El-Deiry WS (2003) *Tumor Suppressor Genes*, Humana Press Inc.

- Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*, **316**, 1039-43.
- Eriksson A, Yachnin J, Lewensohn R, Nilsson A (2001) DNA-dependent protein kinase is inhibited by trifluoperazine. *Biochem Biophys Res Commun*, **283**, 726-31.
- Escudier B, Eisen T, Stadler WM, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*, **356**, 125-34.
- Esteller M, Fraga MF, Guo M, et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. *Hum Mol Genet*, **10**, 3001-7.
- Esteva FJ, Valero V, Booser D, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. *J Clin Oncol*, **20**, 1800-8.
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. *Bmj*, **330**, 1304-5.
- Eychene A, Barnier JV, Apiou F, Dutrillaux B, Calothy G (1992) Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. *Oncogene*, **7**, 1657-60.
- Farmer H, McCabe N, Lord CJ, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **434**, 917-21.
- Fearnhead NS, Britton MP, Bodmer WF (2001) The ABC of APC. *Hum Mol Genet*, **10**, 721-33.
- Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. *Cell*, **61**, 759-67.
- Flaherty KT (2007) Sorafenib in renal cell carcinoma. *Clin Cancer Res*, **13**, 747s-752s.
- Fletcher JA, Rubin BP (2007) KIT mutations in GIST. *Curr Opin Genet Dev*, **17**, 3-7.
- Francke U (1976) Retinoblastoma and chromosome 13. *Birth Defects Orig Artic Ser*, **12**, 131-4.
- Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. *Cancer Cell*, **5**, 317-28.
- Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol*, **21**, 2237-46.
- Fukushige S, Matsubara K, Yoshida M, et al. (1986) Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. *Mol Cell Biol*, **6**, 955-8.
- Fukushima T, Suzuki S, Mashiko M, et al. (2003) BRAF mutations in papillary carcinomas of the thyroid. *Oncogene*, **22**, 6455-7.
- Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH (2005) Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. *Proc Natl Acad Sci U S A*, **102**, 9176-81.
- Futreal PA, Coin L, Marshall M, et al. (2004) A census of human cancer genes. *Nat Rev Cancer*, **4**, 177-83.

- Futreal PA, Liu Q, Shattuck-Eidens D, et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. *Science*, **266**, 120-2.
- Futreal PA, Wooster R, Stratton MR (2005) Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. *Cold Spring Harb Symp Quant Biol*, **70**, 43-9.
- Ganiatsas S, Kwee L, Fujiwara Y, et al. (1998) SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. *Proc Natl Acad Sci U S A*, **95**, 6881-6.
- Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. *Cancer Cell*, **6**, 313-9.
- Garraway LA, Widlund HR, Rubin MA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature*, **436**, 117-22.
- Gatzemeier U, Groth G, Butts C, et al. (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol*, **15**, 19-27.
- Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. *Cell*, **55**, 185-92.
- Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med*, **355**, 2733-43.
- Gibas Z, Becher R, Kawinski E, Horoszewicz J, Sandberg AA (1984) A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). *Cancer Genet Cytogenet*, **11**, 399-404.
- Gil-Ad I, Shtaf B, Levkovitz Y, Dayag M, Zeldich E, Weizman A (2004) Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. *J Mol Neurosci*, **22**, 189-98.
- Gil-Ad I, Shtaf B, Levkovitz Y, et al. (2006) Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. *Oncol Rep*, **15**, 107-12.
- Giordano S, Bardelli A, Zhen Z, Menard S, Ponzetto C, Comoglio PM (1997) A point mutation in the MET oncogene abrogates metastasis without affecting transformation. *Proc Natl Acad Sci U S A*, **94**, 13868-72.
- Gire V, Wynford-Thomas D (2000) RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. *Oncogene*, **19**, 737-44.
- Goetz MP, Ames MM, Weinshilboum RM (2004) Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model. *Mayo Clin Proc*, **79**, 376-84.
- Goetz MP, Knox SK, Suman VJ, et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. *Breast Cancer Res Treat*, **101**, 113-21.
- Gold JS, Dematteo RP (2006) Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. *Ann Surg*, **244**, 176-84.
- Gorre ME, Mohammed M, Ellwood K, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science*, **293**, 876-80.
- Goss KH, Groden J (2000) Biology of the adenomatous polyposis coli tumor suppressor. *J Clin Oncol*, **18**, 1967-79.



- Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996) Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nat Genet*, **12**, 191-4.
- Grace E, Drennan J, Colver D, Gordon RR (1971) The 13q- deletion syndrome. *J Med Genet*, **8**, 351-7.
- Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. *Embo J*, **16**, 1647-55.
- Grbovic OM, Basso AD, Sawai A, et al. (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. *Proc Natl Acad Sci U S A*, **103**, 57-62.
- Greenman C, Stephens P, Smith R, et al. (2007) Patterns of somatic mutation in human cancer genomes. *Nature*, **446**, 153-8.
- Gregorieff A, Clevers H (2005) Wnt signaling in the intestinal epithelium: from endoderm to cancer. *Genes Dev*, **19**, 877-90.
- Greulich H, Chen TH, Feng W, et al. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Med*, **2**, e313.
- Grieco M, Santoro M, Berlingieri MT, et al. (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell*, **60**, 557-63.
- Grinshpoon A, Barchana M, Ponizovsky A, et al. (2005) Cancer in schizophrenia: is the risk higher or lower? *Schizophr Res*, **73**, 333-41.
- Guo M, Liu S, Lu F (2006) Gefitinib-sensitizing mutations in esophageal carcinoma. *N Engl J Med*, **354**, 2193-4.
- Gwak GY, Yoon JH, Shin CM, et al. (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. *J Cancer Res Clin Oncol*, **131**, 649-52.
- Hahn SA, Schutte M, Hoque AT, et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science*, **271**, 350-3.
- Hait WN, Aftab DT (1992) Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. *Biochem Pharmacol*, **43**, 103-7.
- Hall JM, Lee MK, Newman B, et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. *Science*, **250**, 1684-9.
- Han SW, Kim TY, Hwang PG, et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol*, **23**, 2493-501.
- Hanahan D, Weinberg RA (2000) The hallmarks of cancer. *Cell*, **100**, 57-70.
- Harvey JJ (1964) An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice. *Nature*, **204**, 1104-5.
- Hawley TS, Fong AZ, Griesser H, Lyman SD, Hawley RG (1998) Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. *Blood*, **92**, 2003-11.
- He TC, Sparks AB, Rago C, et al. (1998) Identification of c-MYC as a target of the APC pathway. *Science*, **281**, 1509-12.
- Heinrich MC, Corless CL (2005) Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. *J Surg Oncol*, **90**, 195-207; discussion 207.

- Heinrich MC, Corless CL, Blanke CD, et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol*, **24**, 4764-74.
- Heinrich MC, Corless CL, Demetri GD, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol*, **21**, 4342-9.
- Hemminki A, Markie D, Tomlinson I, et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature*, **391**, 184-7.
- Hemminki A, Tomlinson I, Markie D, et al. (1997) Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. *Nat Genet*, **15**, 87-90.
- Henn W, Blin N, Zang KD (1986) Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines. *Hum Genet*, **74**, 104-6.
- Hernan I, Roig I, Martin B, Gamundi MJ, Martinez-Gimeno M, Carballo M (2004) De novo germline mutation in the serine-threonine kinase STK11/LKB1 gene associated with Peutz-Jeghers syndrome. *Clin Genet*, **66**, 58-62.
- Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR (1992) The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. *Genes Dev*, **6**, 177-85.
- Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science*, **279**, 577-80.
- Hirota S, Ohashi A, Nishida T, et al. (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. *Gastroenterology*, **125**, 660-7.
- Hofstra RM, Landsvater RM, Ceccherini I, et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. *Nature*, **367**, 375-6.
- Horowitz JM, Park SH, Bogenmann E, et al. (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. *Proc Natl Acad Sci U S A*, **87**, 2775-9.
- Houben R, Becker JC, Kappel A, et al. (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. *J Carcinog*, **3**, 6.
- Howe JR, Roth S, Ringold JC, et al. (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. *Science*, **280**, 1086-8.
- Howlett NG, Taniguchi T, Olson S, et al. (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. *Science*, **297**, 606-9.
- Hsieh JK, Chan FS, O'Connor DJ, Mitnacht S, Zhong S, Lu X (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. *Mol Cell*, **3**, 181-93.
- Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. *Proc Natl Acad Sci U S A*, **84**, 7159-63.
- Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. *Nature*, **373**, 347-9.

- Hung MC, Schechter AL, Chevray PY, Stern DF, Weinberg RA (1986) Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. *Proc Natl Acad Sci U S A*, **83**, 261-4.
- Hung MC, Zhang X, Yan DH, et al. (1992) Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. *Cancer Lett*, **61**, 95-103.
- Hussain S, Wilson JB, Medhurst AL, et al. (2004) Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. *Hum Mol Genet*, **13**, 1241-8.
- IARC International Agency for Research on Cancer ([www.iarc.fr](http://www.iarc.fr)).
- Ikediodi ON, Davies H, Bignell G, et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. *Mol Cancer Ther*, **5**, 2606-12.
- Inoue A, Suzuki T, Fukuhara T, et al. (2006) Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. *J Clin Oncol*, **24**, 3340-6.
- Ishizaka Y, Itoh F, Tahira T, et al. (1989) Human ret proto-oncogene mapped to chromosome 10q11.2. *Oncogene*, **4**, 1519-21.
- Iwashita T, Murakami H, Asai N, Takahashi M (1996) Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. *Hum Mol Genet*, **5**, 1577-80.
- Iyer L, Hall D, Das S, et al. (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. *Clin Pharmacol Ther*, **65**, 576-82.
- Iyer L, King CD, Whittington PF, et al. (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. *J Clin Invest*, **101**, 847-54.
- Jeffers M, Schmidt L, Nakaigawa N, et al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer. *Proc Natl Acad Sci U S A*, **94**, 11445-50.
- Jenne DE, Reimann H, Nezu J, et al. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet*, **18**, 38-43.
- Ji H, Zhao X, Yuza Y, et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. *Proc Natl Acad Sci U S A*, **103**, 7817-22.
- Joensuu H (2006a) Gastrointestinal stromal tumor (GIST). *Ann Oncol*, **17 Suppl 10**, x280-6.
- Joensuu H (2006b) Sunitinib for imatinib-resistant GIST. *Lancet*, **368**, 1303-4.
- Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med*, **344**, 1052-6.
- Jousse C, Averous J, Bruhat A, Carraro V, Mordier S, Fafournoux P (2004) Amino acids as regulators of gene expression: molecular mechanisms. *Biochem Biophys Res Commun*, **313**, 447-52.
- Kakiuchi S, Daigo Y, Ishikawa N, et al. (2004) Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). *Hum Mol Genet*, **13**, 3029-43.

- Kalinsky K, Haluska FG (2007) Novel inhibitors in the treatment of metastatic melanoma. *Expert Rev Anticancer Ther*, **7**, 715-24.
- Kamb A, Shattuck-Eidens D, Eeles R, et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. *Nat Genet*, **8**, 23-6.
- Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. *Proc Natl Acad Sci U S A*, **97**, 10430-5.
- Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. *Cancer Res*, **50**, 1715-20.
- Kang SM, Kang HJ, Shin JH, et al. (2007) Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. *Cancer*, **109**, 581-7.
- Kantarjian H, Giles F, Wunderle L, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N Engl J Med*, **354**, 2542-51.
- Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. *Br J Cancer*, **94**, 455-9.
- Karasarides M, Chiloehes A, Hayward R, et al. (2004) B-RAF is a therapeutic target in melanoma. *Oncogene*, **23**, 6292-8.
- Katajisto P, Vallenius T, Vaahtomeri K, et al. (2007) The LKB1 tumor suppressor kinase in human disease. *Biochim Biophys Acta*, **1775**, 63-75.
- Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. *Annu Rev Cell Dev Biol*, **17**, 615-75.
- Kau TR, Schroeder F, Ramaswamy S, et al. (2003) A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. *Cancer Cell*, **4**, 463-76.
- Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe N, Niitsu Y (1995) Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. *Mol Cell Biol*, **15**, 1175-81.
- Kaye FJ (2005) A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity? *J Natl Cancer Inst*, **97**, 621-3.
- Kelsell DP, Black DM, Bishop DT, Spurr NK (1993) Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. *Hum Mol Genet*, **2**, 1823-8.
- Kemphues KJ, Kusch M, Wolf N (1988) Maternal-effect lethal mutations on linkage group II of *Caenorhabditis elegans*. *Genetics*, **120**, 977-86.
- Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E (2002) The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. *J Biol Chem*, **277**, 29792-802.

- Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. *J Clin Oncol*, **22**, 4991-5004.
- Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res*, **63**, 1454-7.
- Kirsten WH, Mayer LA, Welander CW (1966) Infective and noninfective viral murine leukemias. *Natl Cancer Inst Monogr*, **22**, 369-77.
- Kiyoi H, Naoe T (2006) Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. *Int J Hematol*, **83**, 301-8.
- Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. *Oncogene*, **21**, 2555-63.
- Klein C, Vassilev LT (2004) Targeting the p53-MDM2 interaction to treat cancer. *Br J Cancer*, **91**, 1415-9.
- Knudson AG, Jr. (1985) Hereditary cancer, oncogenes, and antioncogenes. *Cancer Res*, **45**, 1437-43.
- Knudson AG (2002) Cancer genetics. *Am J Med Genet*, **111**, 96-102.
- Kobayashi S, Boggon TJ, Dayaram T, et al. (2005a) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med*, **352**, 786-92.
- Kobayashi S, Ji H, Yuza Y, et al. (2005b) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. *Cancer Res*, **65**, 7096-101.
- Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. *Biochem J*, **351 Pt 2**, 289-305.
- Koo HM, Monks A, Mikheev A, et al. (1996) Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. *Cancer Res*, **56**, 5211-6.
- Kottaridis PD, Gale RE, Frew ME, et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood*, **98**, 1752-9.
- Krainer M, Silva-Arrieta S, FitzGerald MG, et al. (1997) Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. *N Engl J Med*, **336**, 1416-21.
- Kraus C, Liehr T, Hulsken J, et al. (1994) Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. *Genomics*, **23**, 272-4.
- Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. *Oncogene*, **19**, 5435-43.

- Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A (2001) Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. *Nature*, **413**, 83-6.
- Kris MG, Natale RB, Herbst RS, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *Jama*, **290**, 2149-58.
- Kris RM, Lax I, Sasson I, et al. (1985) Synthetic peptide approach to the analysis of kinase activities of avian EGF receptor and v-erbB protein. *Biochimie*, **67**, 1095-101.
- Kumar R, Angelini S, Czene K, et al. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. *Clin Cancer Res*, **9**, 3362-8.
- Kwabi-Addo B, Giri D, Schmidt K, et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. *Proc Natl Acad Sci U S A*, **98**, 11563-8.
- Kwak EL, Jankowski J, Thayer SP, et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. *Clin Cancer Res*, **12**, 4283-7.
- Kwak EL, Sordella R, Bell DW, et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc Natl Acad Sci U S A*, **102**, 7665-70.
- Lacroix H, Iglehart JD, Skinner MA, Kraus MH (1989) Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. *Oncogene*, **4**, 145-51.
- Lancaster JM, Wooster R, Mangion J, et al. (1996) BRCA2 mutations in primary breast and ovarian cancers. *Nat Genet*, **13**, 238-40.
- Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH (2004) Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. *J Clin Oncol*, **22**, 1180-7.
- Latif F, Tory K, Gnarr J, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science*, **260**, 1317-20.
- Latres E, Malumbres M, Sotillo R, et al. (2000) Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. *Embo J*, **19**, 3496-506.
- Laurie NA, Donovan SL, Shih CS, et al. (2006) Inactivation of the p53 pathway in retinoblastoma. *Nature*, **444**, 61-6.
- le Coutre P, Tassi E, Varella-Garcia M, et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. *Blood*, **95**, 1758-66.
- Lee EY, Chang CY, Hu N, et al. (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. *Nature*, **359**, 288-94.
- Lee JW, Soung YH, Kim SY, et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. *Clin Cancer Res*, **11**, 2879-82.

- Lee JW, Soung YH, Seo SH, et al. (2006a) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. *Clin Cancer Res*, **12**, 57-61.
- Lee SC, Lim SG, Soo R, et al. (2006b) Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. *Pharmacogenet Genomics*, **16**, 73-4.
- Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ (1990) Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. *Oncogene*, **5**, 237-9.
- Lepourcelet M, Chen YN, France DS, et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. *Cancer Cell*, **5**, 91-102.
- Leslie NR, Downes CP (2004) PTEN function: how normal cells control it and tumour cells lose it. *Biochem J*, **382**, 1-11.
- Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. *Nature*, **351**, 453-6.
- Li DM, Sun H (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. *Proc Natl Acad Sci U S A*, **95**, 15406-11.
- Li FP, Fletcher JA, Heinrich MC, et al. (2005) Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. *J Clin Oncol*, **23**, 2735-43.
- Li FP, Fraumeni JF, Jr. (1982) Prospective study of a family cancer syndrome. *Jama*, **247**, 2692-4.
- Li J, Yen C, Liaw D, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science*, **275**, 1943-7.
- Libermann TA, Nusbaum HR, Razon N, et al. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. *Nature*, **313**, 144-7.
- Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H (1984) Expression of epidermal growth factor receptors in human brain tumors. *Cancer Res*, **44**, 753-60.
- Lindpaintner K (2002) The impact of pharmacogenetics and pharmacogenomics on drug discovery. *Nat Rev Drug Discov*, **1**, 463-9.
- Linehan WM, Zbar B (2004) Focus on kidney cancer. *Cancer Cell*, **6**, 223-8.
- Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF (1997) Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. *Proc Natl Acad Sci U S A*, **94**, 10669-74.
- Lizcano JM, Goransson O, Toth R, et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *Embo J*, **23**, 833-43.
- Lohmann DR (1999) RB1 gene mutations in retinoblastoma. *Hum Mutat*, **14**, 283-8.
- Lohmann DR, Brandt B, Hopping W, Passarge E, Horsthemke B (1996) The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. *Am J Hum Genet*, **58**, 940-9.

- Lorenzi PL, Reinhold WC, Rudelius M, et al. (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. *Mol Cancer Ther*, **5**, 2613-23.
- Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). *J Natl Cancer Inst*, **93**, 1852-7.
- Ludwig JA, Szakacs G, Martin SE, et al. (2006) Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. *Cancer Res*, **66**, 4808-15.
- Lundgren R, Kristoffersson U, Heim S, Mandahl N, Mitelman F (1988) Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate. *Cancer Genet Cytogenet*, **35**, 103-8.
- Lynch TJ, Bell DW, Sordella R, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, **350**, 2129-39.
- Ma PC, Jagadeeswaran R, Jagadeesh S, et al. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. *Cancer Res*, **65**, 1479-88.
- Ma YY, Wei SJ, Lin YC, et al. (2000) PIK3CA as an oncogene in cervical cancer. *Oncogene*, **19**, 2739-44.
- Mackarechtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. *Immunity*, **3**, 147-61.
- Mahakrishnan A, Srinivasan MS (1980) Piebaldness with Hirschsprung's disease. *Arch Dermatol*, **116**, 1102.
- Malkin D, Li FP, Strong LC, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science*, **250**, 1233-8.
- Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. *Nat Rev Cancer*, **3**, 459-65.
- Manley PW, Cowan-Jacob SW, Buchdunger E, et al. (2002) Imatinib: a selective tyrosine kinase inhibitor. *Eur J Cancer*, **38 Suppl 5**, S19-27.
- Manley PW, Cowan-Jacob SW, Mestan J (2005) Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. *Biochim Biophys Acta*, **1754**, 3-13.
- Mann B, Gelos M, Siedow A, et al. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. *Proc Natl Acad Sci U S A*, **96**, 1603-8.
- Marsh S, McLeod HL (2006) Pharmacogenomics: from bedside to clinical practice. *Hum Mol Genet*, **15 Spec No 1**, R89-93.
- Martin SG, St Johnston D (2003) A role for *Drosophila* LKB1 in anterior-posterior axis formation and epithelial polarity. *Nature*, **421**, 379-84.
- Mathijssen RH, Marsh S, Karlsson MO, et al. (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. *Clin Cancer Res*, **9**, 3246-53.



- Matsui T, Heidaran M, Miki T, et al. (1989) Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. *Science*, **243**, 800-4.
- Mattei MG, d'Auriol, L., Andre, C., Passage, E., Mattei, J.F., Galibert, F. (1987) Assignment of the human c-kit proto-oncogene to the q11-q12 region of chromosome 4, using in situ hybridization. *Cytogenet Cell Genet*, **46**, abstract.
- Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS (2001) Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. *J Biol Chem*, **276**, 43175-81.
- Maxwell PH, Wiesener MS, Chang GW, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature*, **399**, 271-5.
- McCrea PD, Turck CW, Gumbiner B (1991) A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. *Science*, **254**, 1359-61.
- McKenna HJ, Stocking KL, Miller RE, et al. (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. *Blood*, **95**, 3489-97.
- Mellinghoff IK, Wang MY, Vivanco I, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *N Engl J Med*, **353**, 2012-24.
- Melnick JS, Janes J, Kim S, et al. (2006) An efficient rapid system for profiling the cellular activities of molecular libraries. *Proc Natl Acad Sci U S A*, **103**, 3153-8.
- Michor F, Hughes TP, Iwasa Y, et al. (2005) Dynamics of chronic myeloid leukaemia. *Nature*, **435**, 1267-70.
- Miki Y, Swensen J, Shattuck-Eidens D, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*, **266**, 66-71.
- Mitsudomi T, Kosaka T, Endoh H, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. *J Clin Oncol*, **23**, 2513-20.
- Miyaki M, Konishi M, Kikuchi-Yanoshita R, et al. (1994) Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. *Cancer Res*, **54**, 3011-20.
- Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM (2002) Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. *Cancer Res*, **62**, 2261-6.
- Miyoshi Y, Nagase H, Ando H, et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. *Hum Mol Genet*, **1**, 229-33.
- Mor A, Philips MR (2006) Compartmentalized Ras/MAPK signaling. *Annu Rev Immunol*, **24**, 771-800.
- Morin PJ, Sparks AB, Korinek V, et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science*, **275**, 1787-90.
- Mortensen PB (1994) The occurrence of cancer in first admitted schizophrenic patients. *Schizophr Res*, **12**, 185-94.

- Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. *Cancer Res*, **62**, 3151-8.
- Mulligan LM, Kwok JB, Healey CS, et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature*, **363**, 458-60.
- Murphree AL, Benedict WF (1984) Retinoblastoma: clues to human oncogenesis. *Science*, **223**, 1028-33.
- Myers TG, Anderson NL, Waltham M, et al. (1997) A protein expression database for the molecular pharmacology of cancer. *Electrophoresis*, **18**, 647-53.
- Nagahara H, Mimori K, Ohta M, et al. (2005) Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. *Clin Cancer Res*, **11**, 1368-71.
- Nagata Y, Lan KH, Zhou X, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell*, **6**, 117-27.
- Nagy P, Friedlander E, Tanner M, et al. (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. *Cancer Res*, **65**, 473-82.
- Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. *Cancer Lett*, **232**, 123-38.
- Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. *Cancer Res*, **64**, 2343-6.
- Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. *Nat Clin Pract Oncol*, **3**, 269-80.
- Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. *Cancer Res*, **65**, 11118-28.
- Nakao M, Yokota S, Iwai T, et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. *Leukemia*, **10**, 1911-8.
- Naoe T, Kiyoi H (2004) Normal and oncogenic FLT3. *Cell Mol Life Sci*, **61**, 2932-8.
- Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. *Nat Rev Cancer*, **4**, 665-76.
- Nathke I (2004) APC at a glance. *J Cell Sci*, **117**, 4873-5.
- Nelen MR, van Staveren WC, Peeters EA, et al. (1997) Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. *Hum Mol Genet*, **6**, 1383-7.
- Newbatt Y, Burns S, Hayward R, et al. (2006) Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. *J Biomol Screen*, **11**, 145-54.
- Nicholson RI, Gee JM, Harper ME (2001a) EGFR and cancer prognosis. *Eur J Cancer*, **37 Suppl 4**, S9-15.
- Nicholson RI, Hutcheson IR, Harper ME, et al. (2001b) Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. *Endocr Relat Cancer*, **8**, 175-82.

- Nicolini FE, Corm S, Le QH, et al. (2006) Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). *Leukemia*, **20**, 1061-6.
- Nigro JM, Baker SJ, Preisinger AC, et al. (1989) Mutations in the p53 gene occur in diverse human tumour types. *Nature*, **342**, 705-8.
- Nishida T, Hirota S, Taniguchi M, et al. (1998) Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. *Nat Genet*, **19**, 323-4.
- Nishina H, Fischer KD, Radvanyi L, et al. (1997) Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. *Nature*, **385**, 350-3.
- Nishizuka S, Charboneau L, Young L, et al. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. *Proc Natl Acad Sci U S A*, **100**, 14229-34.
- Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A (1999) Effects of psychotropic drugs on cell proliferation and differentiation. *Biochem Pharmacol*, **58**, 1229-36.
- Nordling CO (1953) A new theory on cancer-inducing mechanism. *Br J Cancer*, **7**, 68-72.
- Nowell PC (1976) The clonal evolution of tumor cell populations. *Science*, **194**, 23-8.
- O'Connor PM, Jackman J, Bae I, et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. *Cancer Res*, **57**, 4285-300.
- O'Dwyer PJ, Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. *J Clin Oncol*, **24**, 4534-8.
- Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. *Nature*, **358**, 80-3.
- OMIM Online Mendelian Inheritance in Man ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)).
- Organization WH.).
- Ozeki K, Kiyoi H, Hirose Y, et al. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. *Blood*, **103**, 1901-8.
- Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. *Cell*, **28**, 865-71.
- Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*, **304**, 1497-500.
- Pao W, Miller V, Zakowski M, et al. (2004a) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*, **101**, 13306-11.
- Pao W, Miller VA, Politi KA, et al. (2005a) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med*, **2**, e73.

- Pao W, Miller VA, Venkatraman E, Kris MG (2004b) Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? *J Natl Cancer Inst*, **96**, 1117-9.
- Pao W, Wang TY, Riely GJ, et al. (2005b) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med*, **2**, e17.
- Parada LF, Tabin CJ, Shih C, Weinberg RA (1982) Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. *Nature*, **297**, 474-8.
- Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. *Proc Natl Acad Sci U S A*, **84**, 6379-83.
- Park WS, Oh RR, Kim YS, et al. (2000) Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. *Apmis*, **108**, 195-200.
- Pasini B, Borrello MG, Greco A, et al. (1995) Loss of function effect of RET mutations causing Hirschsprung disease. *Nat Genet*, **10**, 35-40.
- Paull KD, Shoemaker RH, Hodes L, et al. (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. *J Natl Cancer Inst*, **81**, 1088-92.
- Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M (2001) Direct DNA binding by Brca1. *Proc Natl Acad Sci U S A*, **98**, 6086-91.
- Payne SR, Kemp CJ (2005) Tumor suppressor genetics. *Carcinogenesis*, **26**, 2031-45.
- Peng H, Shen N, Qian L, et al. (2001) Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells. *Br J Cancer*, **85**, 930-5.
- Perren TJ (1991) c-erbB-2 oncogene as a prognostic marker in breast cancer. *Br J Cancer*, **63**, 328-32.
- Petitjean A, Mathe E, Kato S, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. *Hum Mutat*, **28**, 622-9.
- Petty EM, Gibson LH, Fountain JW, et al. (1993) Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). *Am J Hum Genet*, **53**, 96-104.
- Pollock PM, Harper UL, Hansen KS, et al. (2003) High frequency of BRAF mutations in nevi. *Nat Genet*, **33**, 19-20.
- Ponder BA (1999) The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. *Cancer Res*, **59**, 1736s-1741s; discussion 1742s.
- Powell SM, Zilz N, Beazer-Barclay Y, et al. (1992) APC mutations occur early during colorectal tumorigenesis. *Nature*, **359**, 235-7.
- Powers MV, Workman P (2006) Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. *Endocr Relat Cancer*, **13 Suppl 1**, S125-35.

- Price-Schiavi SA, Jepson S, Li P, et al. (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. *Int J Cancer*, **99**, 783-91.
- Qian CN, Guo X, Cao B, et al. (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. *Cancer Res*, **62**, 589-96.
- Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature*, **418**, 934.
- Ranade K, Hussussian CJ, Sikorski RS, et al. (1995) Mutations associated with familial melanoma impair p16INK4 function. *Nat Genet*, **10**, 114-6.
- Renan MJ (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. *Mol Carcinog*, **7**, 139-46.
- Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER (1998) Molecular genetic analysis of von Hippel-Lindau disease. *J Intern Med*, **243**, 527-33.
- Riely GJ, Pao W, Pham D, et al. (2006a) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clin Cancer Res*, **12**, 839-44.
- Riely GJ, Politi KA, Miller VA, Pao W (2006b) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. *Clin Cancer Res*, **12**, 7232-41.
- Romeo G, Ronchetto P, Luo Y, et al. (1994) Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. *Nature*, **367**, 377-8.
- Rong S, Segal S, Anver M, Resau JH, Vande Woude GF (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. *Proc Natl Acad Sci U S A*, **91**, 4731-5.
- Roschke AV, Tonon G, Gehlhaus KS, et al. (2003) Karyotypic complexity of the NCI-60 drug-screening panel. *Cancer Res*, **63**, 8634-47.
- Roskoski R, Jr. (2003) STI-571: an anticancer protein-tyrosine kinase inhibitor. *Biochem Biophys Res Commun*, **309**, 709-17.
- Roskoski R, Jr. (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. *Biochem Biophys Res Commun*, **319**, 1-11.
- Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D (1991a) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene*, **6**, 1641-50.
- Rosnet O, Mattei MG, Marchetto S, Birnbaum D (1991b) Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. *Genomics*, **9**, 380-5.
- Rosnet O, Stephenson D, Mattei MG, et al. (1993) Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse. *Oncogene*, **8**, 173-9.
- Ross DT, Scherf U, Eisen MB, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. *Nat Genet*, **24**, 227-35.
- Rossi DJ, Ylikorkala A, Korsisaari N, et al. (2002) Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. *Proc Natl Acad Sci U S A*, **99**, 12327-32.

- Salvatore D, Barone MV, Salvatore G, et al. (2000) Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. *J Clin Endocrinol Metab*, **85**, 3898-907.
- Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell*, **7**, 561-73.
- Sanchez I, Hughes RT, Mayer BJ, et al. (1994) Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. *Nature*, **372**, 794-8.
- Santoro M, Carlomagno F, Romano A, et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. *Science*, **267**, 381-3.
- Sattler M, Salgia R (2007) c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. *Curr Oncol Rep*, **9**, 102-8.
- Savage DG, Antman KH (2002) Imatinib mesylate--a new oral targeted therapy. *N Engl J Med*, **346**, 683-93.
- Scherf U, Ross DT, Waltham M, et al. (2000) A gene expression database for the molecular pharmacology of cancer. *Nat Genet*, **24**, 236-44.
- Schilder RJ, Sill MW, Chen X, et al. (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. *Clin Cancer Res*, **11**, 5539-48.
- Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. *Science*, **289**, 1938-42.
- Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. *Cell*, **103**, 211-25.
- Schleuning M, Brumme V, Wilmanns W (1993) Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. *Anticancer Res*, **13**, 599-602.
- Schmidt L, Duh FM, Chen F, et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet*, **16**, 68-73.
- Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. *Nat Rev Cancer*, **7**, 295-308.
- Schubbert S, Zenker M, Rowe SL, et al. (2006) Germline KRAS mutations cause Noonan syndrome. *Nat Genet*, **38**, 331-6.
- Schubert D, Heinemann S, Carlisle W, et al. (1974) Clonal cell lines from the rat central nervous system. *Nature*, **249**, 224-7.
- Schutte M, Hruban RH, Hedrick L, et al. (1996) DPC4 gene in various tumor types. *Cancer Res*, **56**, 2527-30.
- Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signalling molecules. *Nature*, **441**, 457-62.
- Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA (1988) Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. *Mol Cell Biol*, **8**, 5570-4.
- Seidman AD, Fornier MN, Esteva FJ, et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy

- by HER2 immunophenotype and gene amplification. *J Clin Oncol*, **19**, 2587-95.
- Seizinger BR, Rouleau GA, Ozelius LJ, et al. (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. *Nature*, **332**, 268-9.
- Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. *Proc Natl Acad Sci U S A*, **82**, 6497-501.
- Sharan SK, Morimatsu M, Albrecht U, et al. (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. *Nature*, **386**, 804-10.
- Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer*, **7**, 169-81.
- Shaw RJ, Lamia KA, Vasquez D, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science*, **310**, 1642-6.
- Shayesteh L, Lu Y, Kuo WL, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. *Nat Genet*, **21**, 99-102.
- Sherr CJ (2001) The INK4a/ARF network in tumour suppression. *Nat Rev Mol Cell Biol*, **2**, 731-7.
- Sherr CJ (2004) Principles of tumor suppression. *Cell*, **116**, 235-46.
- Shi D, He G, Cao S, et al. (1992) Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. *Mol Carcinog*, **5**, 213-8.
- Shigematsu H, Lin L, Takahashi T, et al. (2005a) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst*, **97**, 339-46.
- Shigematsu H, Takahashi T, Nomura M, et al. (2005b) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. *Cancer Res*, **65**, 1642-6.
- Shih C, Padhy LC, Murray M, Weinberg RA (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature*, **290**, 261-4.
- Shih TY, Weeks MO, Young HA, Scolnick EM (1979) p21 of Kirsten murine sarcoma virus is thermolabile in a viral mutant temperature sensitive for the maintenance of transformation. *J Virol*, **31**, 546-6.
- Shimamura T, Ji H, Minami Y, et al. (2006) Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV\_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. *Cancer Res*, **66**, 6487-91.
- Shimizu K, Goldfarb M, Perucho M, Wigler M (1983a) Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. *Proc Natl Acad Sci U S A*, **80**, 383-7.
- Shimizu K, Goldfarb M, Suard Y, et al. (1983b) Three human transforming genes are related to the viral ras oncogenes. *Proc Natl Acad Sci U S A*, **80**, 2112-6.
- Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. *Nat Rev Cancer*, **6**, 813-23.

- Sjoblom T, Jones S, Wood LD, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. *Science*, **314**, 268-74.
- Slamon DJ, Godolphin W, Jones LA, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*, **244**, 707-12.
- Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, **344**, 783-92.
- Small D, Levenstein M, Kim E, et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. *Proc Natl Acad Sci U S A*, **91**, 459-63.
- Smith PE (1992) Familial breast and ovarian cancers. *Semin Oncol Nurs*, **8**, 258-64.
- Smolen GA, Sordella R, Muir B, et al. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. *Proc Natl Acad Sci U S A*, **103**, 2316-21.
- Solit DB, Garraway LA, Pratilas CA, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. *Nature*, **439**, 358-62.
- Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science*, **305**, 1163-7.
- Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. *Nat Rev Cancer*, **1**, 233-40.
- Soverini S, Martinelli G, Rosti G, et al. (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. *J Clin Oncol*, **23**, 4100-9.
- Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM (1999) Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. *Proc Natl Acad Sci U S A*, **96**, 13920-5.
- Spencer SL, Gerety RA, Pienta KJ, Forrest S (2006) Modeling somatic evolution in tumorigenesis. *PLoS Comput Biol*, **2**, e108.
- Spritz RA, Droetto S, Fukushima Y (1992) Deletion of the KIT and PDGFRA genes in a patient with piebaldism. *Am J Med Genet*, **44**, 492-5.
- Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. *Lancet Oncol*, **4**, 397-406.
- Stambolic V, Suzuki A, de la Pompa JL, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. *Cell*, **95**, 29-39.
- Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-kinases as drug targets in cancer. *Curr Opin Pharmacol*, **5**, 357-65.
- Stephens P, Hunter C, Bignell G, et al. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. *Nature*, **431**, 525-6.



- Stephenson DA, Mercola M, Anderson E, et al. (1991) Platelet-derived growth factor receptor alpha-subunit gene (Pdgfra) is deleted in the mouse patch (Ph) mutation. *Proc Natl Acad Sci U S A*, **88**, 6-10.
- Stolle C, Glenn G, Zbar B, et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum Mutat*, **12**, 417-23.
- Stone S, Jiang P, Dayananth P, et al. (1995) Complex structure and regulation of the P16 (MTS1) locus. *Cancer Res*, **55**, 2988-94.
- Stratton MR, Ford D, Neuhasen S, et al. (1994) Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. *Nat Genet*, **7**, 103-7.
- Stratton MR, Futreal PA (2004) Cancer: understanding the target. *Nature*, **430**, 30.
- Su GH, Hilgers W, Shekher MC, et al. (1998) Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. *Cancer Res*, **58**, 2339-42.
- Su GH, Song JJ, Repasky EA, Schutte M, Kern SE (2002) Mutation rate of MAP2K4/MKK4 in breast carcinoma. *Hum Mutat*, **19**, 81.
- Subramanian S, West RB, Corless CL, et al. (2004) Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. *Oncogene*, **23**, 7780-90.
- Sunaga N, Tomizawa Y, Yanagitani N, et al. (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. *Lung Cancer*, **56**, 383-9.
- Sutani A, Nagai Y, Udagawa K, et al. (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. *Br J Cancer*, **95**, 1483-9.
- Suzuki A, de la Pompa JL, Hakem R, et al. (1997) Brca2 is required for embryonic cellular proliferation in the mouse. *Genes Dev*, **11**, 1242-52.
- Szakacs G, Annereau JP, Lababidi S, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. *Cancer Cell*, **6**, 129-37.
- Tabin CJ, Bradley SM, Bargmann CI, et al. (1982) Mechanism of activation of a human oncogene. *Nature*, **300**, 143-9.
- Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. *Cell*, **42**, 581-8.
- Takahashi T, Nau MM, Chiba I, et al. (1989) p53: a frequent target for genetic abnormalities in lung cancer. *Science*, **246**, 491-4.
- Talpaz M, Shah NP, Kantarjian H, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *N Engl J Med*, **354**, 2531-41.
- Tarn C, Merkel E, Canutescu AA, et al. (2005) Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. *Clin Cancer Res*, **11**, 3668-77.
- Taya Y (1997) RB kinases and RB-binding proteins: new points of view. *Trends Biochem Sci*, **22**, 14-7.
- ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. *Trends Biochem Sci*, **29**, 265-73.

- Teng DH, Bogden R, Mitchell J, et al. (1996) Low incidence of BRCA2 mutations in breast carcinoma and other cancers. *Nat Genet*, **13**, 241-4.
- Teng DH, Perry WL, 3rd, Hogan JK, et al. (1997) Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. *Cancer Res*, **57**, 4177-82.
- Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*, **398**, 422-6.
- Thiagalingam S, Lengauer C, Leach FS, et al. (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. *Nat Genet*, **13**, 343-6.
- Thomas RK, Baker AC, DeBiasi RM, et al. (2007) High-throughput oncogene mutation profiling in human cancer. *Nat Genet*, **39**, 347-51.
- Thurlimann B, Keshaviah A, Coates AS, et al. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med*, **353**, 2747-57.
- Tokarski JS, Newitt JA, Chang CY, et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. *Cancer Res*, **66**, 5790-7.
- Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. *Nat Rev Cancer*, **6**, 909-23.
- Trent JM, Wiltshire R, Su LK, Nicolaides NC, Vogelstein B, Kinzler KW (1995) The gene for the APC-binding protein beta-catenin (CTNNB1) maps to chromosome 3p22, a region frequently altered in human malignancies. *Cytogenet Cell Genet*, **71**, 343-4.
- Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. *J Invest Dermatol*, **122**, 337-41.
- Tsao MS, Sakurada A, Cutz JC, et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. *N Engl J Med*, **353**, 133-44.
- Tuveson DA, Willis NA, Jacks T, et al. (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. *Oncogene*, **20**, 5054-8.
- Udd L, Katajisto P, Rossi DJ, et al. (2004) Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. *Gastroenterology*, **127**, 1030-7.
- Uramoto H, Sugio K, Oyama T, et al. (2006) Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. *Lung Cancer*, **51**, 71-7.
- Verweij J, Casali PG, Zalcberg J, et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet*, **364**, 1127-34.
- Verweij J, van Oosterom A, Blay JY, et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. *Eur J Cancer*, **39**, 2006-11.

- Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat Rev Cancer*, **2**, 489-501.
- Vogel CL, Cobleigh MA, Tripathy D, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol*, **20**, 719-26.
- Vogelstein B, Fearon ER, Hamilton SR, et al. (1988) Genetic alterations during colorectal-tumor development. *N Engl J Med*, **319**, 525-32.
- Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. *Cell*, **70**, 523-6.
- Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. *Nat Med*, **10**, 789-99.
- Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. *Nature*, **408**, 307-10.
- Wan PT, Garnett MJ, Roe SM, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell*, **116**, 855-67.
- Wang SE, Narasanna A, Perez-Torres M, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell*, **10**, 25-38.
- Wardelmann E, Hrychuk A, Merkelbach-Bruse S, et al. (2004) Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. *J Mol Diagn*, **6**, 197-204.
- Weinberg RA (2007) *The biology of cancer.*, Garland Science, Taylor & Francis Group, LLC.
- Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bedside. *Nat Rev Drug Discov*, **3**, 739-48.
- Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet*, **32**, 651-62.
- Weinstein JN (2004) Integromic analysis of the NCI-60 cancer cell lines. *Breast Dis*, **19**, 11-22.
- Weinstein JN, Kohn KW, Grever MR, et al. (1992) Neural computing in cancer drug development: predicting mechanism of action. *Science*, **258**, 447-51.
- Weinstein JN, Myers TG, O'Connor PM, et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. *Science*, **275**, 343-9.
- Weinstein JN, Pommier Y (2003) Transcriptomic analysis of the NCI-60 cancer cell lines. *C R Biol*, **326**, 909-20.
- Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. *Blood*, **95**, 3498-505.
- Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. *Nat Rev Cancer*, **7**, 345-56.
- White RA, Hughes RT, Adkison LR, Bruns G, Zon LI (1996) The gene encoding protein kinase SEK1 maps to mouse chromosome 11 and human chromosome 17. *Genomics*, **34**, 430-2.

- WHO World Health Organization ([www.who.int/cancer](http://www.who.int/cancer)).
- Whyte DB, Holbeck SL (2006) Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. *Biochem Biophys Res Commun*, **340**, 469-75.
- Wilhelm SM, Carter C, Tang L, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res*, **64**, 7099-109.
- Wilson MG, Towner JW, Fujimoto A (1973) Retinoblastoma and D-chromosome deletions. *Am J Hum Genet*, **25**, 57-61.
- Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. *Annu Rev Cell Dev Biol*, **14**, 59-88.
- Wooster R, Bignell G, Lancaster J, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. *Nature*, **378**, 789-92.
- Wooster R, Neuhausen SL, Mangion J, et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. *Science*, **265**, 2088-90.
- Wu MS, Lee CW, Shun CT, et al. (2000) Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. *Genes Chromosomes Cancer*, **27**, 403-11.
- Xia W, Bacus S, Hegde P, et al. (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. *Proc Natl Acad Sci U S A*, **103**, 7795-800.
- Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. *Oncogene*, **24**, 6213-21.
- Xu X, Brodie SG, Yang X, et al. (2000) Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. *Oncogene*, **19**, 1868-74.
- Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. *Cancer Res*, **62**, 4132-41.
- Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. *J Biol Chem*, **279**, 40419-30.
- Yamamoto Y, Kiyoi H, Nakano Y, et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. *Blood*, **97**, 2434-9.
- Yamazaki H, Fukui Y, Ueyama Y, et al. (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. *Mol Cell Biol*, **8**, 1816-20.
- Yan M, Templeton DJ (1994) Identification of 2 serine residues of MEK-1 that are differentially phosphorylated during activation by raf and MEK kinase. *J Biol Chem*, **269**, 19067-73.

- Yarden Y (2001) Biology of HER2 and its importance in breast cancer. *Oncology*, **61 Suppl 2**, 1-13.
- Ylikorkala A, Avizienyte E, Tomlinson IP, et al. (1999) Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. *Hum Mol Genet*, **8**, 45-51.
- Ylikorkala A, Rossi DJ, Korsisaari N, et al. (2001) Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. *Science*, **293**, 1323-6.
- Yu J, Miehlik S, Ebert MP, et al. (2000) Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. *Cancer*, **88**, 1801-6.
- Yuen ST, Davies H, Chan TL, et al. (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. *Cancer Res*, **62**, 6451-5.
- Yun H, Lee M, Kim SS, Ha J (2005) Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. *J Biol Chem*, **280**, 9963-72.
- Zbar B, Kishida T, Chen F, et al. (1996) Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. *Hum Mutat*, **8**, 348-57.
- Zermati Y, De Sepulveda P, Feger F, et al. (2003) Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. *Oncogene*, **22**, 660-4.
- Zhang X, Chang A (2007) Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. *J Med Genet*, **44**, 166-72.
- Zhou HE, Zhang X, von Eschenbach AC, et al. (1990) Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. *Mol Carcinog*, **3**, 254-7.
- Zhelev Z, Ohba H, Bakalova R, et al. (2004) Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. *Cancer Chemother Pharmacol*, **53**, 267-75.
- Zhong Q, Chen CF, Li S, et al. (1999) Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. *Science*, **285**, 747-50.
- Zhou BB, Peyton M, He B, et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*, **10**, 39-50.
- Zhu HG, Tayeh I, Israel L, Castagna M (1991) Different susceptibility of lung cell lines to inhibitors of tumor promotion and inducers of differentiation. *J Biol Regul Homeost Agents*, **5**, 52-8.
- Zhuang Z, Park WS, Pack S, et al. (1998) Trisomy 7-harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. *Nat Genet*, **20**, 66-9.
- Zinner RG, Glisson BS, Fossella FV, et al. (2004) Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. *Lung Cancer*, **44**, 99-110.

